Vinblastine
- Generic Name
- Vinblastine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H58N4O9
- CAS Number
- 865-21-4
- Unique Ingredient Identifier
- 5V9KLZ54CY
- Background
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
- Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
- Associated Conditions
- Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
- Associated Therapies
- -
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
- Conditions
- Anterior Urethral CancerLocalized Transitional Cell Cancer of the Renal Pelvis and UreterPosterior Urethral CancerRecurrent Bladder CancerRecurrent Urethral CancerRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerTransitional Cell Carcinoma of the BladderUreter CancerUrethral Cancer Associated With Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT01639521
Metronomic Therapy in Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT01542255
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
- Conditions
- Interventions
- Drug: brentuximab vedotinDrug: doxorubicin hydrochlorideDrug: vinblastineDrug: dacarbazineProcedure: quality-of-life assessmentGenetic: DNA analysisGenetic: RNA analysisRadiation: fludeoxyglucose F 18Procedure: positron emission tomographyOther: laboratory biomarker analysisOther: immunohistochemistry staining methodGenetic: polymorphism analysis
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 48
- Registration Number
- NCT01476410
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Memorial Sloan- Kettering Cancer Center, New York, New York, United States
Prospective Study on HIV-related Hodgkin Lymphoma
- Conditions
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Harlachinger Krebshilfe e.V.
- Target Recruit Count
- 130
- Registration Number
- NCT01468740
- Locations
- 🇩🇪
Infektionsmedizinisches Zentrum Hamburg, Hamburg, Germany
🇩🇪Vivantes Auguste Victoria Klinikum, Berlin, Germany
🇩🇪Ärzteforum Seestrasse, Berlin, Germany
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 6
- Registration Number
- NCT01390584
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 331
- Registration Number
- NCT01251107
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 226
- Registration Number
- NCT01148446
- Locations
- 🇮🇹
Ospedale San Sebastiano, Correggio (RE), Italy
🇮🇹Istituto Vito Fazzi, Lecce, Italy
🇮🇹S.C. di Ematologia, Spedali Civili, Brescia, Italy
Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 610
- Registration Number
- NCT01134861
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01060904
- Locations
- 🇺🇸
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 30
- Registration Number
- NCT01056679
- Locations
- 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, NRW, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.